TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.
Identifieur interne : 002778 ( Main/Exploration ); précédent : 002777; suivant : 002779TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.
Auteurs : K Bailey Freund [Suisse] ; Jean-François Korobelnik ; Robert Devenyi ; Carsten Framme ; John Galic ; Edward Herbert ; Hans Hoerauf ; Paolo Lanzetta ; Stephan Michels ; Paul Mitchell ; Jordi Monés ; Carl Regillo ; Ramin Tadayoni ; James Talks ; Sebastian WolfSource :
- Retina (Philadelphia, Pa.) [ 1539-2864 ] ; 2015.
Descripteurs français
- KwdFr :
- Algorithmes, Bévacizumab (usage thérapeutique), Dégénérescence maculaire (traitement médicamenteux), Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs), Humains, Inhibiteurs de l'angiogenèse (usage thérapeutique), Occlusion veineuse rétinienne (traitement médicamenteux), Oedème maculaire (traitement médicamenteux), Protéines de fusion recombinantes (usage thérapeutique), Ranibizumab (usage thérapeutique), Récepteurs aux facteurs de croissance endothéliale vasculaire (usage thérapeutique), Rétinopathie diabétique (traitement médicamenteux).
- MESH :
- antagonistes et inhibiteurs : Facteur de croissance endothéliale vasculaire de type A.
- traitement médicamenteux : Dégénérescence maculaire, Occlusion veineuse rétinienne, Oedème maculaire, Rétinopathie diabétique.
- usage thérapeutique : Bévacizumab, Inhibiteurs de l'angiogenèse, Protéines de fusion recombinantes, Ranibizumab, Récepteurs aux facteurs de croissance endothéliale vasculaire.
- Algorithmes, Humains.
English descriptors
- KwdEn :
- Algorithms, Angiogenesis Inhibitors (therapeutic use), Bevacizumab (therapeutic use), Diabetic Retinopathy (drug therapy), Humans, Macular Degeneration (drug therapy), Macular Edema (drug therapy), Ranibizumab (therapeutic use), Receptors, Vascular Endothelial Growth Factor (therapeutic use), Recombinant Fusion Proteins (therapeutic use), Retinal Vein Occlusion (drug therapy), Vascular Endothelial Growth Factor A (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Vascular Endothelial Growth Factor A.
- chemical , therapeutic use : Angiogenesis Inhibitors, Bevacizumab, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- drug therapy : Diabetic Retinopathy, Macular Degeneration, Macular Edema, Retinal Vein Occlusion.
- Algorithms, Humans.
Abstract
A review of treat-and-extend regimens (TERs) with intravitreal anti-vascular endothelial growth factor agents in retinal diseases.
DOI: 10.1097/IAE.0000000000000627
PubMed: 26076215
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002B07
- to stream PubMed, to step Curation: 002A36
- to stream PubMed, to step Checkpoint: 002A36
- to stream Ncbi, to step Merge: 002708
- to stream Ncbi, to step Curation: 002708
- to stream Ncbi, to step Checkpoint: 002708
- to stream Main, to step Merge: 002778
- to stream Main, to step Curation: 002778
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.</title><author><name sortKey="Freund, K Bailey" sort="Freund, K Bailey" uniqKey="Freund K" first="K Bailey" last="Freund">K Bailey Freund</name><affiliation wicri:level="3"><nlm:affiliation>*Vitreous Retina Macula Consultants of New York and Department of Ophthalmology, New York University Langone Medical Center, New York, New York; †Ophthalmology Service, CHU de Bordeaux, Bordeaux, France and INSERM, ISPED, Centre INSERM U897-Epidemiology-Biostatistics, Bordeaux, France; ‡The Donald K. Johnson Eye Center, The University Health Network, Toronto; The University of Toronto, Toronto, Canada; §University Eye Hospital Hannover, Hannover, Germany; ¶Montreal Retina Institute, Montreal, Canada; **Musgrove Park Hospital, Taunton, United Kingdom; ††Eye Clinic, Medical University, Göttingen, Germany; ‡‡Department of Medical and Biological Sciences, Ophthalmology, University of Udine, IEMO-Istituto Europeo di Microchirurgia Oculare, Udine, Italy; §§Department of Ophthalmology, City Hospital Triemli, Zurich; University of Zurich, Zurich, Switzerland; ¶¶Centre for Vision Research, Westmead Millennium Institute, University of Sydney, New South Wales, Australia; ***Macula and Retina Institute, Hospital Quiron Teknon, Barcelona; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain; †††Retina Service and Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7 Sorbonne Paris Cité, Paris, France; §§§Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and ¶¶¶Department of Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>*Vitreous Retina Macula Consultants of New York and Department of Ophthalmology, New York University Langone Medical Center, New York, New York; †Ophthalmology Service, CHU de Bordeaux, Bordeaux, France and INSERM, ISPED, Centre INSERM U897-Epidemiology-Biostatistics, Bordeaux, France; ‡The Donald K. Johnson Eye Center, The University Health Network, Toronto; The University of Toronto, Toronto, Canada; §University Eye Hospital Hannover, Hannover, Germany; ¶Montreal Retina Institute, Montreal, Canada; **Musgrove Park Hospital, Taunton, United Kingdom; ††Eye Clinic, Medical University, Göttingen, Germany; ‡‡Department of Medical and Biological Sciences, Ophthalmology, University of Udine, IEMO-Istituto Europeo di Microchirurgia Oculare, Udine, Italy; §§Department of Ophthalmology, City Hospital Triemli, Zurich; University of Zurich, Zurich, Switzerland; ¶¶Centre for Vision Research, Westmead Millennium Institute, University of Sydney, New South Wales, Australia; ***Macula and Retina Institute, Hospital Quiron Teknon, Barcelona; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain; †††Retina Service and Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7 Sorbonne Paris Cité, Paris, France; §§§Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and ¶¶¶Department of Ophthalmology, Inselspital, University Hospital, University of Bern, Bern</wicri:regionArea><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Korobelnik, Jean Francois" sort="Korobelnik, Jean Francois" uniqKey="Korobelnik J" first="Jean-François" last="Korobelnik">Jean-François Korobelnik</name></author><author><name sortKey="Devenyi, Robert" sort="Devenyi, Robert" uniqKey="Devenyi R" first="Robert" last="Devenyi">Robert Devenyi</name></author><author><name sortKey="Framme, Carsten" sort="Framme, Carsten" uniqKey="Framme C" first="Carsten" last="Framme">Carsten Framme</name></author><author><name sortKey="Galic, John" sort="Galic, John" uniqKey="Galic J" first="John" last="Galic">John Galic</name></author><author><name sortKey="Herbert, Edward" sort="Herbert, Edward" uniqKey="Herbert E" first="Edward" last="Herbert">Edward Herbert</name></author><author><name sortKey="Hoerauf, Hans" sort="Hoerauf, Hans" uniqKey="Hoerauf H" first="Hans" last="Hoerauf">Hans Hoerauf</name></author><author><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name></author><author><name sortKey="Michels, Stephan" sort="Michels, Stephan" uniqKey="Michels S" first="Stephan" last="Michels">Stephan Michels</name></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name></author><author><name sortKey="Mones, Jordi" sort="Mones, Jordi" uniqKey="Mones J" first="Jordi" last="Monés">Jordi Monés</name></author><author><name sortKey="Regillo, Carl" sort="Regillo, Carl" uniqKey="Regillo C" first="Carl" last="Regillo">Carl Regillo</name></author><author><name sortKey="Tadayoni, Ramin" sort="Tadayoni, Ramin" uniqKey="Tadayoni R" first="Ramin" last="Tadayoni">Ramin Tadayoni</name></author><author><name sortKey="Talks, James" sort="Talks, James" uniqKey="Talks J" first="James" last="Talks">James Talks</name></author><author><name sortKey="Wolf, Sebastian" sort="Wolf, Sebastian" uniqKey="Wolf S" first="Sebastian" last="Wolf">Sebastian Wolf</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26076215</idno><idno type="pmid">26076215</idno><idno type="doi">10.1097/IAE.0000000000000627</idno><idno type="wicri:Area/PubMed/Corpus">002B07</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B07</idno><idno type="wicri:Area/PubMed/Curation">002A36</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A36</idno><idno type="wicri:Area/PubMed/Checkpoint">002A36</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A36</idno><idno type="wicri:Area/Ncbi/Merge">002708</idno><idno type="wicri:Area/Ncbi/Curation">002708</idno><idno type="wicri:Area/Ncbi/Checkpoint">002708</idno><idno type="wicri:Area/Main/Merge">002778</idno><idno type="wicri:Area/Main/Curation">002778</idno><idno type="wicri:Area/Main/Exploration">002778</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.</title><author><name sortKey="Freund, K Bailey" sort="Freund, K Bailey" uniqKey="Freund K" first="K Bailey" last="Freund">K Bailey Freund</name><affiliation wicri:level="3"><nlm:affiliation>*Vitreous Retina Macula Consultants of New York and Department of Ophthalmology, New York University Langone Medical Center, New York, New York; †Ophthalmology Service, CHU de Bordeaux, Bordeaux, France and INSERM, ISPED, Centre INSERM U897-Epidemiology-Biostatistics, Bordeaux, France; ‡The Donald K. Johnson Eye Center, The University Health Network, Toronto; The University of Toronto, Toronto, Canada; §University Eye Hospital Hannover, Hannover, Germany; ¶Montreal Retina Institute, Montreal, Canada; **Musgrove Park Hospital, Taunton, United Kingdom; ††Eye Clinic, Medical University, Göttingen, Germany; ‡‡Department of Medical and Biological Sciences, Ophthalmology, University of Udine, IEMO-Istituto Europeo di Microchirurgia Oculare, Udine, Italy; §§Department of Ophthalmology, City Hospital Triemli, Zurich; University of Zurich, Zurich, Switzerland; ¶¶Centre for Vision Research, Westmead Millennium Institute, University of Sydney, New South Wales, Australia; ***Macula and Retina Institute, Hospital Quiron Teknon, Barcelona; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain; †††Retina Service and Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7 Sorbonne Paris Cité, Paris, France; §§§Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and ¶¶¶Department of Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>*Vitreous Retina Macula Consultants of New York and Department of Ophthalmology, New York University Langone Medical Center, New York, New York; †Ophthalmology Service, CHU de Bordeaux, Bordeaux, France and INSERM, ISPED, Centre INSERM U897-Epidemiology-Biostatistics, Bordeaux, France; ‡The Donald K. Johnson Eye Center, The University Health Network, Toronto; The University of Toronto, Toronto, Canada; §University Eye Hospital Hannover, Hannover, Germany; ¶Montreal Retina Institute, Montreal, Canada; **Musgrove Park Hospital, Taunton, United Kingdom; ††Eye Clinic, Medical University, Göttingen, Germany; ‡‡Department of Medical and Biological Sciences, Ophthalmology, University of Udine, IEMO-Istituto Europeo di Microchirurgia Oculare, Udine, Italy; §§Department of Ophthalmology, City Hospital Triemli, Zurich; University of Zurich, Zurich, Switzerland; ¶¶Centre for Vision Research, Westmead Millennium Institute, University of Sydney, New South Wales, Australia; ***Macula and Retina Institute, Hospital Quiron Teknon, Barcelona; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain; †††Retina Service and Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7 Sorbonne Paris Cité, Paris, France; §§§Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and ¶¶¶Department of Ophthalmology, Inselspital, University Hospital, University of Bern, Bern</wicri:regionArea><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Korobelnik, Jean Francois" sort="Korobelnik, Jean Francois" uniqKey="Korobelnik J" first="Jean-François" last="Korobelnik">Jean-François Korobelnik</name></author><author><name sortKey="Devenyi, Robert" sort="Devenyi, Robert" uniqKey="Devenyi R" first="Robert" last="Devenyi">Robert Devenyi</name></author><author><name sortKey="Framme, Carsten" sort="Framme, Carsten" uniqKey="Framme C" first="Carsten" last="Framme">Carsten Framme</name></author><author><name sortKey="Galic, John" sort="Galic, John" uniqKey="Galic J" first="John" last="Galic">John Galic</name></author><author><name sortKey="Herbert, Edward" sort="Herbert, Edward" uniqKey="Herbert E" first="Edward" last="Herbert">Edward Herbert</name></author><author><name sortKey="Hoerauf, Hans" sort="Hoerauf, Hans" uniqKey="Hoerauf H" first="Hans" last="Hoerauf">Hans Hoerauf</name></author><author><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name></author><author><name sortKey="Michels, Stephan" sort="Michels, Stephan" uniqKey="Michels S" first="Stephan" last="Michels">Stephan Michels</name></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name></author><author><name sortKey="Mones, Jordi" sort="Mones, Jordi" uniqKey="Mones J" first="Jordi" last="Monés">Jordi Monés</name></author><author><name sortKey="Regillo, Carl" sort="Regillo, Carl" uniqKey="Regillo C" first="Carl" last="Regillo">Carl Regillo</name></author><author><name sortKey="Tadayoni, Ramin" sort="Tadayoni, Ramin" uniqKey="Tadayoni R" first="Ramin" last="Tadayoni">Ramin Tadayoni</name></author><author><name sortKey="Talks, James" sort="Talks, James" uniqKey="Talks J" first="James" last="Talks">James Talks</name></author><author><name sortKey="Wolf, Sebastian" sort="Wolf, Sebastian" uniqKey="Wolf S" first="Sebastian" last="Wolf">Sebastian Wolf</name></author></analytic><series><title level="j">Retina (Philadelphia, Pa.)</title><idno type="eISSN">1539-2864</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Algorithms</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Bevacizumab (therapeutic use)</term><term>Diabetic Retinopathy (drug therapy)</term><term>Humans</term><term>Macular Degeneration (drug therapy)</term><term>Macular Edema (drug therapy)</term><term>Ranibizumab (therapeutic use)</term><term>Receptors, Vascular Endothelial Growth Factor (therapeutic use)</term><term>Recombinant Fusion Proteins (therapeutic use)</term><term>Retinal Vein Occlusion (drug therapy)</term><term>Vascular Endothelial Growth Factor A (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Algorithmes</term><term>Bévacizumab (usage thérapeutique)</term><term>Dégénérescence maculaire (traitement médicamenteux)</term><term>Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs)</term><term>Humains</term><term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term><term>Occlusion veineuse rétinienne (traitement médicamenteux)</term><term>Oedème maculaire (traitement médicamenteux)</term><term>Protéines de fusion recombinantes (usage thérapeutique)</term><term>Ranibizumab (usage thérapeutique)</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire (usage thérapeutique)</term><term>Rétinopathie diabétique (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Bevacizumab</term><term>Ranibizumab</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type A</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetic Retinopathy</term><term>Macular Degeneration</term><term>Macular Edema</term><term>Retinal Vein Occlusion</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dégénérescence maculaire</term><term>Occlusion veineuse rétinienne</term><term>Oedème maculaire</term><term>Rétinopathie diabétique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Bévacizumab</term><term>Inhibiteurs de l'angiogenèse</term><term>Protéines de fusion recombinantes</term><term>Ranibizumab</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Algorithms</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Algorithmes</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A review of treat-and-extend regimens (TERs) with intravitreal anti-vascular endothelial growth factor agents in retinal diseases.</div></front></TEI><affiliations><list><country><li>Suisse</li></country><region><li>Canton de Berne</li></region><settlement><li>Berne</li></settlement></list><tree><noCountry><name sortKey="Devenyi, Robert" sort="Devenyi, Robert" uniqKey="Devenyi R" first="Robert" last="Devenyi">Robert Devenyi</name><name sortKey="Framme, Carsten" sort="Framme, Carsten" uniqKey="Framme C" first="Carsten" last="Framme">Carsten Framme</name><name sortKey="Galic, John" sort="Galic, John" uniqKey="Galic J" first="John" last="Galic">John Galic</name><name sortKey="Herbert, Edward" sort="Herbert, Edward" uniqKey="Herbert E" first="Edward" last="Herbert">Edward Herbert</name><name sortKey="Hoerauf, Hans" sort="Hoerauf, Hans" uniqKey="Hoerauf H" first="Hans" last="Hoerauf">Hans Hoerauf</name><name sortKey="Korobelnik, Jean Francois" sort="Korobelnik, Jean Francois" uniqKey="Korobelnik J" first="Jean-François" last="Korobelnik">Jean-François Korobelnik</name><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name><name sortKey="Michels, Stephan" sort="Michels, Stephan" uniqKey="Michels S" first="Stephan" last="Michels">Stephan Michels</name><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name><name sortKey="Mones, Jordi" sort="Mones, Jordi" uniqKey="Mones J" first="Jordi" last="Monés">Jordi Monés</name><name sortKey="Regillo, Carl" sort="Regillo, Carl" uniqKey="Regillo C" first="Carl" last="Regillo">Carl Regillo</name><name sortKey="Tadayoni, Ramin" sort="Tadayoni, Ramin" uniqKey="Tadayoni R" first="Ramin" last="Tadayoni">Ramin Tadayoni</name><name sortKey="Talks, James" sort="Talks, James" uniqKey="Talks J" first="James" last="Talks">James Talks</name><name sortKey="Wolf, Sebastian" sort="Wolf, Sebastian" uniqKey="Wolf S" first="Sebastian" last="Wolf">Sebastian Wolf</name></noCountry><country name="Suisse"><region name="Canton de Berne"><name sortKey="Freund, K Bailey" sort="Freund, K Bailey" uniqKey="Freund K" first="K Bailey" last="Freund">K Bailey Freund</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002778 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002778 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26076215
|texte= TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26076215" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |